June 2010 Issue
After evaluating technologies, Lonza Biologics is implementing a Raman-based raw materials identification process. QC manager Derek Hubley explains why, and how.
No matter how we dress it up, PAT, "Product Assurance" Technology is still about control.
L2 measures 51 pharma brands on their digital IQs...how does your brand stack-up?
Is pharma's transformation from a batch-only universe now upon us?
21 CFR 314.70, and the process by which FDA reviews changes to already approved applications, needs a risk-based update, now. Consultant Ali Afnan, formerly with FDA, makes his case.
Pharma has many customers today. But is it focusing on the ones that will help it improve quality and drive innovation?
Pharma's Lean Six Sigma efforts are still at an early stage, but Toyota's quality woes offer important lessons
If supplier audits could be harmonized and shared amongst trusted partners, "we could effectively revolutionize the entire industry" and make our supply chains much safer, says Sigma-Aldrich's Tom Beil.
HCD breaks from traditional development where marketing writes requirements and engineering builds something.